Hematological Malignancies clinical trials at UCSF
2 in progress, 1 open to eligible people
A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma
open to eligible people ages 18 years and up
The purpose of this study is evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).
San Francisco, California and other locations
Compassionate Use Study of Tenalisib (RP6530)
Sorry, accepting new patients by invitation only
Tenalisib has been evaluated as an investigational new drug in number of early clinical studies in patients with relapsed/refractory hematological malignancies and demonstrated acceptable safety and promising efficacy in these patients. Since these advanced relapsed/refractory patients have limited therapeutic options, it is reasonable to continue Tenalisib in responding patients post completion of their participation in previous clinical studies.
San Francisco, California and other locations
Last updated: